Skip to content

cross-reactivity between phenobarbital and topiramate

Evaluation of cross-reactivity between phenobarbital and topiramate in epileptic children entering to mofid children hospital

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2012071010239N1
Enrollment
43
Registered
2013-02-09
Start date
2011-09-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

seizure. Episodic and paroxysmal disorders

Interventions

we prescribe topiramate for intervention group.the initial dose is 2 mg /kg/day,increase incrementally to up to 10 mg /kg/day twice daily. we use three forms of topiramate that is made in Iran, dos
Treatment - Drugs

Sponsors

Pediatric Neurology Research center OF Shahid Beheshti University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 14 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria : Children aged between 0 to 14 years with a history of seizure that need to treatment? Epileptic children have used Phenobarbital for treatment ? Patients show signs and symptoms of hypersensivity to Phenobarbital. Exclusion criteria: Children aged greater than 14 years ? Children who used combination therapy? patients have had history of infection or hypersensivity to other materials recently.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
DRUG COSS-REACTION. Timepoint: At a period of six months. Method of measurement: Exam and observation.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFackredin Shariatmadary

Pediatric Neurology Research Center

shariat.8666@yahoo.com+98 21 2290 9559

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026